# The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)

> **NCT07671924** · PHASE2 · RECRUITING · sponsor: **Trevi Therapeutics** · enrollment: 100 (estimated)

## Conditions studied

- Refractory Chronic Cough

## Interventions

- **DRUG:** NAL ER
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07671924
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671924, "The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*